Évaluation de l’immunotoxicité en recherche et dans le cadre du développement biomédical

Accès gratuit

Numéro		Biologie Aujourd’hui Volume 216, Numéro 3-4, 2022


Page(s)		167 - 181
DOI		https://doi.org/10.1051/jbio/2022020
Publié en ligne		6 février 2023

Ai, W., Li, H., Song, N., Li, L., Chen, H. (2013). Optimal method to stimulate cytokine production and its use in immunotoxicity assessment. Int J Environ Res Public Health, 10, 3834–3842. [CrossRef] [PubMed] [Google Scholar]
American College of Toxicology. (2020). Fundamental approaches to immunotoxicity assessment in preclinical safety studies. https://interact.actox.org/viewdocument/fundamental-approaches-to-immunotox. [Google Scholar]
Anderson, S.E., Shane, H.L. (2018). Investigative immunotoxicology. Methods Mol Biol, 1803, 27–46. [CrossRef] [PubMed] [Google Scholar]
Auguste, M., Melillo, D., Corteggio, A., Marino, R., Canesi, L., Pinsino, A., Italiani, P., Boraschi, D. (2022). Methodological approaches to assess innate immunity and innate memory in marine invertebrates and humans. Front Toxicol, 4, 842469. [CrossRef] [PubMed] [Google Scholar]
Bannish, G. (2018). The importance of immunopharmacology in non-clinical safety assessment of immune-oncology biotherapeutics. https://www.toxicology.org/groups/rc/NorCal/docs/20180501-presentation-greg-bannish-v2.pdf. [Google Scholar]
Boisseau, C., Perrot, S. (2012). Évaluation de l’immunotoxicité d’une molécule pharmaceutique (chimique ou biologique) en développement : Bilan des tests disponibles et proposition d’un arbre de décisions pour l’identification des dangers et l’évaluation du risque immunotoxique, École vétérinaire de Maisons-Alfort, Maisons-Alfort, pp. 1-206. [Google Scholar]
Bouchez, C., Gervais, F., Fleurance, R., Palate, B., Legrand, J.-J., Descotes, J. (2012). Development of a Delayed-Type Hypersensitivity (DTH) model in the Cynomolgus monkey. J Toxicol Pathol, 25, 183-188. [CrossRef] [PubMed] [Google Scholar]
Boverhof, D.R., Ladics, G., Luebke, B., Botham, J., Corsini, E., Evans, E., Germolec, D., Holsapple, M., Loveless, S.E., Lu, H., van der Laan, J.W., White, K.L., Yang, Y. (2014). Approaches and considerations for the assessment of immunotoxicity for environmental chemicals: A workshop summary. Regul Toxicol Pharmacol, 68, 96-107. [CrossRef] [PubMed] [Google Scholar]
Burleson, G.R., Burleson, F.G. (2008). Testing human biologicals in animal host resistance models. J Immunotoxicol, 5, 23-31. [CrossRef] [PubMed] [Google Scholar]
Burleson, S.C.M., Freebern, W.J., Burleson, F.G., Burleson, G.R., Johnson, V.J., Luebke, R.W. (2018). Host resistance assays. Methods Mol Biol, 1803, 117-145. [CrossRef] [PubMed] [Google Scholar]
Burns-Naas, L., Pallardy, M. (2013). Immunotoxicology, in: Nonclinical Safety Assessment: A Guide to International Pharmaceutical Regulations, John Wiley & Sons, Ltd., New Jersey, pp. 313-346. [CrossRef] [Google Scholar]
Chen, H.-C. (2005). Boyden chamber assay. Methods Mol Biol, 294, 15-22. [PubMed] [Google Scholar]
Corsini, E., Loveren, H.V. (2014). Molecular immunotoxicology (1st ed.), Wiley-VCH, Weinheim, pp. 1-329. [Google Scholar]
De Jong, W.H., Van Loveren, H. (2007). Screening of xenobiotics for direct immunotoxicity in an animal study. Methods, 41, 3-8. [CrossRef] [PubMed] [Google Scholar]
Dean, J.H. (2004). A brief history of immunotoxicology and a review of the pharmaceutical guidelines. Int J Toxicol, 23, 83-90. [CrossRef] [PubMed] [Google Scholar]
Dean, J.H., Padarathsingh, M.L., Jerrells, T.R. (1979). Assessment of immunobiological effects induced by chemicals, drugs or food additives. I. Tier testing and screening approach. Drug Chem Toxicol, 2, 5-17. [CrossRef] [PubMed] [Google Scholar]
Dean, J.H., Hincks, J.R., Remandet, B. (1998). Immunotoxicology assessment in the pharmaceutical industry. Toxicol Lett, 102-103, 247-255. [CrossRef] [PubMed] [Google Scholar]
Descotes, J. (2009). Immunotoxicity of monoclonal antibodies. MAbs, 1(2), 104-111. [CrossRef] [PubMed] [Google Scholar]
Descotes, J. (2012). Safety immunopharmacology: Evaluation of the adverse potential of pharmaceuticals on the immune system. J Pharmacol Toxicol Methods, 66, 79-83. [CrossRef] [PubMed] [Google Scholar]
Descotes, J. (2014). Immune system, in: P. Wexler (Ed.), Encyclopedia of toxicology (3rd ed.), Academic Press, pp. 1004-1023. [CrossRef] [Google Scholar]
Dintzis, R.Z., Vogelstein, B., Dintzis, H.M. (1982). Specific cellular stimulation in the primary immune response: Experimental test of a quantized model. Proc Natl Acad Sci USA, 79, 884-888. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
Dobrovolskaia, M.A., McNeil, S.E. (2013). Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines. J Control Release, 172, 456-466. [CrossRef] [PubMed] [Google Scholar]
Elmore, S.A. (2012). Enhanced histopathology of the immune system: A review and update. Toxicol Pathol, 40, 148-156. [CrossRef] [PubMed] [Google Scholar]
EMA. (2018a). ICH S6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. https://www.ema.europa.eu/en/ich-s6-r1-preclinical-safety-evaluation-biotechnology-derived-pharmaceuticals. [Google Scholar]
EMA. (2018b). ICH S8 Immunotoxicity studies for human pharmaceuticals. https://www.ema.europa.eu/en/ich-s8-immunotoxicity-studies-human-pharmaceuticals. [Google Scholar]
Espenschied, S.T., Tighe, R.M., Gowdy, K.M. (2018). Flow cytometry for the immunotoxicologist. Methods Mol Biol, 1803, 183-197. [CrossRef] [PubMed] [Google Scholar]
Farmer, J.T., Dietert, R.R. (2013). Chapter 10 – Immunotoxicology assessment in drug development, in: A.S. Faqi (Ed.), A comprehensive guide to toxicology in nonclinical drug development (2nd ed.), Academic Press, pp. 247-262. [CrossRef] [Google Scholar]
Galbiati, V., Mitjans, M., Corsini, E. (2010). Present and future of in vitro immunotoxicology in drug development. J Immunotoxicol, 7, 255-267. [CrossRef] [PubMed] [Google Scholar]
Germolec, D., Luebke, R., Rooney, A., Shipkowski, K., Vandebriel, R., van Loveren, H. (2017). Immunotoxicology: A brief history, current status and strategies for future immunotoxicity assessment. Curr Opin Toxicol, 5, 55-59. [CrossRef] [PubMed] [Google Scholar]
Germolec, D.R., Shipkowski, K.A., Frawley, R.P., Evans, E. (2018). Markers of inflammation. Methods Mol Biol, 1803, 57-79. [CrossRef] [PubMed] [Google Scholar]
Geyer, H., Wuhrer, M., Resemann, A., Geyer, R. (2005). Identification and characterization of keyhole limpet hemocyanin N-glycans mediating cross-reactivity with Schistosoma mansoni. J Biol Chem, 280, 40731-40748. [CrossRef] [PubMed] [Google Scholar]
Grant, C.F., Lefevre, E.A., Carr, B.V., Prentice, H., Gubbins, S., Pollard, A.J., Charreyre, C., Charleston, B. (2012). Assessment of T-dependent and T-independent immune responses in cattle using a B cell ELISPOT assay. Vet Res, 43, 68. [CrossRef] [PubMed] [Google Scholar]
Grimaldi, C., Finco, D., Fort, M.M., Gliddon, D., Harper, K., Helms, W.S., Mitchell, J.A., O’Lone, R., Parish, S.T., Piche, M.-S., Reed, D.M., Reichmann, G., Ryan, P.C., Stebbings, R., Walker, M. (2016). Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions. Cytokine, 85, 101-108. [CrossRef] [PubMed] [Google Scholar]
Haggerty, H.G. (2007). Immunotoxicity testing in non-rodent species. J Immunotoxicol, 4, 165-169. [CrossRef] [PubMed] [Google Scholar]
Hartung, T., Corsini, E. (2013). Immunotoxicology: Challenges in the 21st century and in vitro opportunities. ALTEX, 30, 411-426. [CrossRef] [PubMed] [Google Scholar]
Janeway, C.J., Travers, P., Walport, M., Shlomchik, M.J. (2001). B-cell activation by armed helper T cells, in: Immunobiology: The immune system in health and disease (5th ed.), Garland Science, New York, pp. 402-426. [Google Scholar]
Karmaus, P.W.F., Karmaus, A.L. (2018). Challenges for integrating immunotoxicology into the twenty-first-century toxicology testing paradigm. Methods Mol Biol, 1803, 385-396. [CrossRef] [PubMed] [Google Scholar]
Kaul, R. (2013). Chapter 917 – Hepatitis, in: The immunoassay handbook (4th ed.), Elsevier, Amsterdam, pp. 901-911. [Google Scholar]
Kawabata, T.T., Evans, E.W. (2012). Development of immunotoxicity testing strategies for immunomodulatory drugs. Toxicol Pathol, 40, 288-293. [Google Scholar]
Kawai, R., Ito, S., Aida, T., Hattori, H., Kimura, T., Furukawa, T., Mori, K., Sanbuissho, A., Kawada, T. (2013). Evaluation of primary and secondary responses to a T-cell-dependent antigen, keyhole limpet hemocyanin, in rats. J Immunotoxicol, 10, 40-48. [CrossRef] [PubMed] [Google Scholar]
Koller, L.D. (2001). A perspective on the progression of immunotoxicology. Toxicology, 160, 105-110. [CrossRef] [PubMed] [Google Scholar]
Kuper, C.F., van Bilsen, J., Cnossen, H., Houben, G., Garthoff, J., Wolterbeek, A. (2016). Development of immune organs and functioning in humans and test animals: Implications for immune intervention studies. Reprod Toxicol, 64, 180-190. [CrossRef] [PubMed] [Google Scholar]
Ladics, G.S. (2018). The sheep erythrocyte T-Dependent Antibody Response (TDAR). Methods Mol Biol, 1803, 83-94. [CrossRef] [PubMed] [Google Scholar]
Lebrec, H., Cowan, L., Lagrou, M., Krejsa, C., Neradilek, M.B., Polissar, N.L., Black, L., Bussière, J. (2011). An inter-laboratory retrospective analysis of immunotoxicological endpoints in non-human primates: T-cell-dependent antibody responses. J Immunotoxicol, 8, 238-250. [CrossRef] [PubMed] [Google Scholar]
Lebrec, H., Molinier, B., Boverhof, D., Collinge, M., Freebern, W., Henson, K., Mytych, D.T., Ochs, H.D., Wange, R., Yang, Y., Zhou, L., Arrington, J., Christin-Piché, M.S., Shenton, J. (2014). The T-cell-dependent antibody response assay in nonclinical studies of pharmaceuticals and chemicals: Study design, data analysis, interpretation. Regul Toxicol Pharmacol, 69, 7-21. [CrossRef] [PubMed] [Google Scholar]
Logel, D.Y., Jaschke, P.R. (2020). A high-resolution map of bacteriophage φX174 transcription. Virology, 547, 47-56. [CrossRef] [Google Scholar]
Lorenzo-Herrero, S., Sordo-Bahamonde, C., González, S., López-Soto, A. (2020). Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay. Methods Enzymol, 631, 483-495. [CrossRef] [PubMed] [Google Scholar]
Luster, M.I. (2014). A historical perspective of immunotoxicology. J Immunotoxicol, 11, 197-202. [CrossRef] [PubMed] [Google Scholar]
Mahalingam, S., Peter, J., Xu, Z., Bordoloi, D., Ho, M., Kalyanaraman, V.S., Srinivasan, A., Muthumani, K. (2021). Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing. Heliyon, 7, e06836. [CrossRef] [PubMed] [Google Scholar]
Martin, P.L. (2010). Chapter 17 – Reproductive toxicity testing for biopharmaceuticals, in: Preclinical safety evaluation of biopharmaceuticals, John Wiley& Sons Ltd., New Jersey, pp. 1-21. [Google Scholar]
Meunier, S., de Bourayne, M., Hamze, M., Azam, A., Correia, E., Menier, C., Maillère, B. (2020). Specificity of the T cell response to protein biopharmaceuticals. Front Immunol, 11, 1550. [CrossRef] [PubMed] [Google Scholar]
Mond, J.J., Vos, Q., Lees, A., Snapper, C.M. (1995). T cell independent antigens. Curr Opin Immunol, 7, 349-354. [CrossRef] [PubMed] [Google Scholar]
Nagarkatti, M., Rieder, S.A., Nagarkatti, P.S. (2018). Evaluation of cell proliferation and apoptosis in immunotoxicity testing. Methods Mol Biol, 1803, 209-230. [CrossRef] [PubMed] [Google Scholar]
OECD. (1998). Test No. 409: Repeated dose 90-day oral toxicity study in non-rodents. https://www.oecd-ilibrary.org/environment/test-no-409-repeated-dose-90-day-oral-toxicity-study-in-non-rodents_9789264070721-en. [CrossRef] [Google Scholar]
OECD. (2008). Test No. 407: Repeated dose 28-day oral toxicity study in rodents. https://www.oecd-ilibrary.org/environment/test-no-407-repeated-dose-28-day-oral-toxicity-study-in-rodents_9789264070684-en. [CrossRef] [Google Scholar]
OECD. (2018). Test No. 443: Extended one-generation reproductive toxicity study. https://www.oecd-ilibrary.org/fr/environment/test-no-443-extended-one-generation-reproductive-toxicity-study_9789264185371-en. [CrossRef] [Google Scholar]
OECD. (2022). Test No. 406: Skin sensitisation. https://www.oecd-ilibrary.org/fr/environment/test-no-406-skin-sensitisation_9789264070660-en. [Google Scholar]
Oellerich, M., Brandhorst, G., Shipkova, M., Wieland, E. (2012). Chapter 16 – Biomarkers: The link between therapeutic drug monitoring and pharmacodynamics of immunosuppressants, in: A. Dasgupta (Ed.), Therapeutic drug monitoring, Academic Press, pp. 349-372. [CrossRef] [PubMed] [Google Scholar]
Orange, J.S., Ballow, M., Stiehm, E.R., Ballas, Z.K., Chinen, J., De La Morena, M., Kumararatne, D., Harville, T.O., Hesterberg, P., Koleilat, M., McGhee, S., Perez, E.E., Raasch, J., Scherzer, R., Schroeder, H., Seroogy, C., Huissoon, A., Sorensen, R.U., Katial, R. (2012). Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol, 130, S1-S24. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
Peachee, V.L., Smith, M.J., Beck, M.J., Stump, D.G., White, K.L. (2014). Characterization of the T-dependent antibody response (TDAR) to keyhole limpet hemocyanin (KLH) in the Göttingen minipig. J Immunotoxicol, 11, 376-382. [CrossRef] [PubMed] [Google Scholar]
Peyton Myers, L. (2018). Clinical immunotoxicology. Methods Mol Biol, 1803, 15-26. [CrossRef] [PubMed] [Google Scholar]
Plitnick, L.M., Herzyk, D.J. (2010). The T-dependent antibody response to keyhole limpet hemocyanin in rodents. Methods Mol Biol, 598, 159-171. [CrossRef] [PubMed] [Google Scholar]
Plunkett, L.M., Kaplan, A.M., Becker, R.A. (2010). An enhanced tiered toxicity testing framework with triggers for assessing hazards and risks of commodity chemicals. Regul Toxicol Pharmacol, 58, 382-394. [CrossRef] [PubMed] [Google Scholar]
Potter, T.M., Neun, B.W., Dobrovolskaia, M.A. (2018). In vitro and in vivo methods for analysis of nanoparticle potential to induce delayed-type hypersensitivity reactions. Methods Mol Biol, 1682, 197-210. [CrossRef] [PubMed] [Google Scholar]
Rabadi, T., Brady, M.F. (2022). Tetanus toxoid. http://www.ncbi.nlm.nih.gov/books/NBK557415/. [Google Scholar]
Richards, L., Erko, B., Ponpetch, K., Ryan, S.J., Liang, S. (2019). Assessing the nonhuman primate reservoir of Schistosoma mansoni in Africa: A systematic review. Infect Dis Poverty, 8, 32. [CrossRef] [PubMed] [Google Scholar]
Rumianek, A.N., Greaves, D.R. (2020). How have leukocyte in vitro chemotaxis assays shaped our ideas about macrophage migration? Biology, 9, E439. [CrossRef] [PubMed] [Google Scholar]
ScienceDirect. (2017). Hepatitis B surface antigen – An overview. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/hepatitis-b-surface-antigen. [Google Scholar]
Sharon, R., McMaster, P.R., Kask, A.M., Owens, J.D., Paul, W.E. (1975). DNP-Lys-ficoll: A T-independent antigen which elicits both IgM and IgG anti-DNP antibody-secreting cells. J Immunol, 114, 1585-1589. [CrossRef] [PubMed] [Google Scholar]
Taylor, L., Recio, C., Greaves, D.R., Iqbal, A.J. (2018). In vitro migration assays. Methods Mol Biol, 1784, 197-214. [CrossRef] [PubMed] [Google Scholar]
The European Commission. (2018). Commission Regulation (EU) 2018/1881. https://eur-lex.europa.eu/eli/reg/2006/1907. [Google Scholar]
Thériaque. (2021a). Monographie DEXAMETHASONE MYL 4MG/1ML SOL INJ. https://www.theriaque.org/apps/monographie/index.php?id=14274&type=SP&popup=1&imprimer=1&info%5B%5D=COMPO&info%5B%5D=CLASS&info%5B%5D=GENE&info%5B%5D=CHOIX&info%5B%5D=ADMIN&info%5B%5D=CONSV&info%5B%5D=INDIC&info%5B%5D=NON_INDIC&info%5B%5D=POSO&info%5B%5D=C_INDIC&info%5B%5D=PREC_EMP&info%5B%5D=N_C_INDIC&info%5B%5D=INTER&info%5B%5D=GROSSESSE&info%5B%5D=CONDUITE&info%5B%5D=EFFET. [Google Scholar]
Thériaque. (2021b). Monographie ENDOXAN 1000MG PDR INJ. https://www.theriaque.org/apps/monographie/index.php?id=8878&type=SP&popup=1&imprimer=1&info%5B%5D=COMPO&info%5B%5D=CLASS&info%5B%5D=GENE&info%5B%5D=CHOIX&info%5B%5D=ADMIN&info%5B%5D=CONSV&info%5B%5D=INDIC&info%5B%5D=NON_INDIC&info%5B%5D=POSO&info%5B%5D=C_INDIC&info%5B%5D=PREC_EMP&info%5B%5D=N_C_INDIC&info%5B%5D=INTER&info%5B%5D=GROSSESSE&info%5B%5D=CONDUITE&info%5B%5D=EFFET. [Google Scholar]
Thériaque. (2021c). Monographie SANDIMMUN 50MG/ML SOL INJ AMP 1ML. https://www.theriaque.org/apps/monographie/index.php?id=4073&type=SP&popup=1&imprimer=1&info%5B%5D=COMPO&info%5B%5D=CLASS&info%5B%5D=GENE&info%5B%5D=CHOIX&info%5B%5D=ADMIN&info%5B%5D=CONSV&info%5B%5D=INDIC&info%5B%5D=NON_INDIC&info%5B%5D=POSO&info%5B%5D=C_INDIC&info%5B%5D=PREC_EMP&info%5B%5D=N_C_INDIC&info%5B%5D=INTER&info%5B%5D=GROSSESSE&info%5B%5D=CONDUITE&info%5B%5D=EFFET. [Google Scholar]
US EPA. (1996a). Biochemicals test guidelines: OPPTS 880.3550 immunotoxicity. https://www.regulations.gov/document/EPA-HQ-OPPT-2009-0158-0005. [Google Scholar]
US EPA. (1996b). Biochemicals test guidelines: OPPTS 880.3800 immune response. https://www.regulations.gov/document/EPA-HQ-OPPT-2009-0158-0006. [Google Scholar]
US EPA. (1996c). Health effects test guidelines: OPPTS 870.7800 immunotoxicity. https://www.regulations.gov/document/EPA-HQ-OPPT-2009-0156-0049. [Google Scholar]
Vos, J.G., Moore, J.A. (1977). Immune suppression as related to toxicology. CRC Crit Rev Toxicol, 5, 67-101. [CrossRef] [PubMed] [Google Scholar]
Yao, W., Ding, M., Bao, L., Zhao, Y., Wang, D., Li, Y., Qu, Y., Hao, C. (2020). Human monocyte-derived dendritic cells as an in vitro alternative model cell to evaluate the immunotoxicity of 2, 4-Dinitrochlorobenzene. Toxicol Lett, 330, 118-127. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.